Fig. 5.

Morbidity and mortality of immunized mice following challenge with an antigenically distinct strain. B6 mice were vaccinated with 0.3 μg of TIV or TIV + rOv-ASP-1; some mice were boosted three weeks later. Mice were infected i.n. with a lethal dose (400TCID₅₀) of influenza virus PR8, at week 3 after primary ((A) and (B)) or booster immunization ((C) and (D)). Survival was defined as ≤25% weight loss for PR8 infection. Three to five mice in each group. (A) and (C) are representative of two experiments with 3–5 mice with similar results. Ten mice/group for (B), and 8–9 mice/group for (D) are the pooled data from the two experiments. ^*p < 0.05.